Open label Dose Escalation Trial of an Adaptive Natural

Project: Research project

Description

Open label Dose Escalation Trial of an Adaptive Natural Killer (NK) Cell Infusion (FATE-NK100) with Subcutaneous IL-2 in Adults with Refractory or Relapsed Acute Myelogenous Leukemia (AML)
StatusActive
Effective start/end date10/1/164/24/20

Funding

  • Fate Therapeutics, Inc.

Fingerprint

Acute Myeloid Leukemia
Natural Killer Cells
Interleukin-2